Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | TGM2 | P21980 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1124538 | 0.90 | TGM2 (0.61) | ALDH1A1TGM2SMN1; SMN2KDM4EGAA | |
| SCHEMBL732934 | 0.86 | TGM2 (0.81) | ALDH1A1TGM2LMNA | |
| SCHEMBL16054315 | 0.83 | TGM2 (0.54) | ALDH1A1TGM2SMN1; SMN2KDM4EHTT | |
| SCHEMBL12707584 | 0.83 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2KDM4EGAAHSD17B10 | |
| SCHEMBL2695687 | 0.83 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2KDM4EGAAHSD17B10 | |
| SCHEMBL10745325 | 0.82 | HDAC2 (0.54) | ALDH1A1SMN1; SMN2KDM4EHSD17B10HTT | |
| SCHEMBL40744 | 0.81 | TGM2 (0.68) | ALDH1A1TGM2SMN1; SMN2GAALMNA | |
| SCHEMBL31321078 | 0.80 | USP2 (0.68) | ALDH1A1SMN1; SMN2MAPTHTTNPSR1 | |
| SCHEMBL774098 | 0.80 | USP2 (0.68) | ALDH1A1SMN1; SMN2MAPTHTTNPSR1 | |
| SCHEMBL31321074 | 0.80 | USP2 (0.68) | ALDH1A1SMN1; SMN2MAPTHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381718-A1 | BARRIERS INCLUDING MOLECULES COVALENTLY BONDED TO AMPHIPHILIC MOLECULES, AND METHODS OF MAKING THE SAME | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| US-20230312857-A1 | NANOPORE DEVICES INCLUDING BARRIERS USING POLYMERS WITH END GROUPS, AND METHODS OF MAKING THE SAME | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-10-05 | — | — | US | disclosed |
| US-20230312856-A1 | NANOPORE DEVICES INCLUDING BARRIERS USING DIBLOCK OR TRIBLOCK COPOLYMERS, AND METHODS OF MAKING THE SAME | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-10-05 | — | — | US | disclosed |
| WO-2023187110-A1 | AMPHIPHILIC POLYMERS TO BE USED IN BARRIERS AND PREPARATION THEREOF, BARRIERS WITH NANOPORES AND PREPARATION THEREOF | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023187106-A1 | BARRIERS INCLUDING CROSS-LINKED AMPHIPHILIC MOLECULES, AND METHODS OF MAKING THE SAME | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-10-05 | — | — | WO | disclosed |
| CN-101516832-B | Process for preparing basic (meth) acrylamides | CLARIANT FINANCE (BVI) LTD. (VG) | 2015-09-09 | — | — | CN | disclosed |
| US-9039870-B2 | Method for producing alkaline (meth)acrylamides | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-05-26 | — | — | US | disclosed |
| US-8895551-B2 | Acrylamide compounds and the use thereof | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| CN-101918354-B | Continuous method for producing amides of ethylenically unsaturated carboxylic acids | CLARIANT INT LTD | 2013-07-17 | — | — | CN | disclosed |
| US-8192918-B2 | Lithographic printing plate precursor | AGFA GRAPHICS NV (BE) | 2012-06-05 | — | — | US | disclosed |
| EP-0134535-B1 | 1,6-NAPHTHYRIDIN DERIVATIVES USEFUL AS CARDIOTONICS AND PREPARATION THEREOF | STERLING DRUG INC. (US) | 1988-10-26 | — | — | EP | disclosed |
| EP-0101952-B1 | 5-ALKYL-1,6-NAPHTHYRIDIN-2(1H)-ONES, INTERMEDIATES, THEIR PREPARATION AND THEIR CARDIOTONIC USE | STERLING DRUG INC. (US) | 1987-09-23 | — | — | EP | disclosed |
| EP-0204335-A2 | 2(1H)-Pyridin-ones useful as intermediates | STERLING DRUG INC. (US) | 1986-12-10 | — | — | EP | disclosed |
| US-4604399-A | 5-methyl(or ethyl)-1,6-naphthyridin-2(1H)-one 6-oxides, their preparation and the cardiotonic use thereof | STERLING DRUG INC. (US) | 1986-08-05 | — | — | US | disclosed |
| US-4559347-A | 3-Substituted-5-alkyl-1,6-naphthyridin-2(1H)-ones, cardiotonic use and preparation thereof | STERLING DRUG INC. (US) | 1985-12-17 | — | — | US | disclosed |
| US-4532247-A | Increases cardiac contractility | STERLING DRUG INC. (US) | 1985-07-30 | — | — | US | disclosed |
| US-4517190-A | 5-Alkyl-1,6-naphthyridin-2(1H)-ones and cardiotonic use thereof | STERLING DRUG INC. (US) | 1985-05-14 | — | — | US | disclosed |
| EP-0134535-A1 | 1,6-Naphthyridin derivatives useful as cardiotonics and preparation thereof | STERLING DRUG INC. (US) | 1985-03-20 | — | — | EP | disclosed |
| EP-0101952-A1 | 5-Alkyl-1,6-naphthyridin-2(1H)-ones, intermediates, their preparation and their cardiotonic use | STERLING DRUG INC. (US) | 1984-03-07 | — | — | EP | disclosed |
| US-4415580-A | Certain 2-(1H)-pyridinones cardiotonic compositions containing same and method of using same | STERLING DRUG INC. (US) | 1983-11-15 | — | — | US | disclosed |